title: An alkali-burn injury model of corneal neovascularization in the mouse.
abstract: Under normal conditions, the cornea is avascular, and this transparency is essential for maintaining good visual acuity. Neovascularization (NV) of the cornea, which can be caused by trauma, keratoplasty or infectious disease, breaks down the so called 'angiogenic privilege' of the cornea and forms the basis of multiple visual pathologies that may even lead to blindness. Although there are several treatment options available, the fundamental medical need presented by corneal neovascular pathologies remains unmet. In order to develop safe, effective, and targeted therapies, a reliable model of corneal NV and pharmacological intervention is required. Here, we describe an alkali-burn injury corneal neovascularization model in the mouse. This protocol provides a method for the application of a controlled alkali-burn injury to the cornea, administration of a pharmacological compound of interest, and visualization of the result. This method could prove instrumental for studying the mechanisms and opportunities for intervention in corneal NV and other neovascular disorders.
authors.forename: Chastain
authors.initials: C
authors.lastname: Anderson
authors.forename: Qinbo
authors.initials: Q
authors.lastname: Zhou
authors.affiliation: Department of Cell and Molecular Biology, Tulane University; Department of Ophthalmology, Tulane University; swang1@tulane.edu.
authors.forename: Shusheng
authors.initials: S
authors.lastname: Wang
mesh_terms: D000818:Animals; D002057:Burns, Chemical; D016510:Corneal Neovascularization; D004195:Disease Models, Animal; D051379:Mice; D012972:Sodium Hydroxide
chemical_list: D012972:Sodium Hydroxide
references.citation: Nat Protoc. 2009;4(11):1565-73
references.pmid: 19816419
references.citation: Mol Pharm. 2013 Jan 7;10(1):307-18
references.pmid: 23186311
references.citation: Acta Ophthalmol. 2008 May;86(3):322-8
references.pmid: 17995975
references.citation: Cornea. 2011 Aug;30(8):927-38
references.pmid: 21389854
references.citation: Bull World Health Organ. 2001;79(3):214-21
references.pmid: 11285665
references.citation: Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2388-95
references.pmid: 15980226
references.citation: Invest Ophthalmol Vis Sci. 1989 Oct;30(10):2148-53
references.pmid: 2477342
references.citation: Acta Ophthalmol. 2014 Mar;92(2):143-8
references.pmid: 22994268
references.citation: Curr Opin Ophthalmol. 2001 Aug;12(4):242-9
references.pmid: 11507336
references.citation: Cornea. 2012 Jul;31(7):804-9
references.pmid: 22467003
references.citation: Invest Ophthalmol Vis Sci. 2013 Mar 01;54(3):1680-8
references.pmid: 23404121
references.citation: J Clin Invest. 2004 Apr;113(7):1040-50
references.pmid: 15057311
references.citation: Lab Invest. 2005 Apr;85(4):474-86
references.pmid: 15696184
references.citation: Ophthalmologe. 2003 Apr;100(4):292-9
references.pmid: 12682761
references.citation: J Cataract Refract Surg. 2011 Mar;37(3):588-98
references.pmid: 21333881
references.citation: Br J Ophthalmol. 2012 May;96(5):614-8
references.pmid: 22133988
references.citation: Br J Ophthalmol. 2012 Jan;96(1):3-9
references.pmid: 21712359
references.citation: Angiogenesis. 2013 Jul;16(3):639-46
references.pmid: 23423728
references.citation: Nature. 2006 Oct 26;443(7114):993-7
references.pmid: 17051153